Clene Inc. — Director's Dealing 2021

Apr 13, 2021

SEC Form 3/A — Form 3/A

Issuer: Clene Inc. (CLNN)
CIK: 0001822791
Period of Report: 2020-12-30

Reporting Person: Mortenson Mark (N/A)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options (Right to buy)	$2.50		Common Stock (263955.00)		Direct
Stock Options (Right to buy)	$0.15		Common Stock (687604.00)		Direct

Footnotes

F1: This Form 3 amendment is being filed to correct an error in the original Form 3 filed on January 4, 2021 to reflect a correction in the exercise price that resulted from an internal calculation error.

F2: Awarded under the Clene Nanomedicine, Inc. 2014 Stock Plan on August 26, 2019 and currently exercisable. The options expire 10 years from the date of the grant.

F3: Awarded the right to buy 6,210,000 shares of Clene Nanomedicine, Inc. common stock under the Clene Nanomedicine, Inc. 2014 Stock Plan on July 31, 2014. The reporting party exercised his right to purchase 1,000,000 shares of Clene Nanomedicine, Inc. common stock on November 23, 2016. Following Clene Nanomedicine, Inc.'s merger, the unexercised options converted into the right to buy common stock of Clene Inc.. The unexercised options now represent the right to buy 687,604 shares of Clene Inc. common stock. The unexercised options are all currently exercisable and expire 10 years from the date of the grant.